The SFDA Regulatory Framework for Drug Approval is the Saudi Food and Drug Authority's master document for how medicines are registered in Saudi Arabia. Currently in Version 6.4, it defines every route a pharmaceutical product can take to marketing authorization — who may apply, which pathway applies to which product, what the SFDA commits to in review timelines, and what it expects from applicants in return. This guide explains how the framework is organized and how to use it to plan a Saudi registration strategy.
What is the SFDA Regulatory Framework for Drug Approval?
It is the SFDA's published reference describing the end-to-end regulation of human medicinal products: new Marketing Authorization Applications (MAA), variations, renewals, and the accelerated programs that sit alongside the standard route. Rather than a single procedure, the framework is a map of procedures — it tells an applicant which pathway their product qualifies for and what evidence each pathway demands.
The framework is revised periodically. Version 6.4 is the current edition, and each revision refines submission requirements, assessment stages, and timelines, so applicants should always plan against the latest version rather than an older download.
The registration pathways under the framework
The framework organizes drug approval into distinct assessment routes, and choosing the right one is the single biggest driver of registration speed:
- Full assessment — complete scientific review of quality, safety, and efficacy data. Applies to new chemical entities and products with no prior approval from a recognized authority.
- Abridged assessment — a reduced review that leverages the assessment work of reference regulatory authorities for products already approved abroad.
- Verification — the fastest route, available when the product holds approval from recognized reference authorities such as the US FDA, EMA, MHRA, Health Canada, TGA, PMDA, or Swissmedic; the SFDA verifies the reference assessment rather than repeating it.
- Accelerated programs — the Breakthrough Medicine Program, priority review, and conditional approval adjust the standard routes for products meeting defined public-health criteria.
What are the SFDA review timelines?
Each pathway carries published target timelines, with verification and abridged routes substantially shorter than full assessment. In practice, the calendar time an applicant experiences is longer than the published review clock: the timeline pauses whenever the SFDA issues questions, and restarts when the applicant responds. Incomplete dossiers and slow query responses — not SFDA processing — are the most common causes of delay.
End to end, companies should plan for roughly nine to eighteen months for a generic on the verification or abridged route, and longer for full-assessment products, including pricing review after the technical assessment concludes.
How submissions work: SDR portal, eCTD, and pricing
All applications under the framework are submitted electronically through the Saudi Drug Registration (SDR) platform as an eCTD dossier — a baseline eCTD submission is a formal requirement, and physical media are no longer accepted practice. Labeling must be prepared bilingually in Arabic and English, and every manufacturing site in the supply chain must hold SFDA GMP clearance before approval can be granted. For the submission process step by step, see our guide to SFDA drug registration in Saudi Arabia.
Approval is also conditional on pricing: after a positive technical assessment, the product passes to the SFDA pricing review, which benchmarks against reference countries before the marketing authorization is issued.
Applicant responsibilities under the framework
The framework is explicit that registration is a shared-responsibility process. Applications must be submitted through a locally licensed entity — an authorized agent or scientific office — and the applicant remains responsible for the accuracy and completeness of the dossier, for responding to SFDA queries within the set deadlines, and for maintaining a local pharmacovigilance system with a Qualified Person for Pharmacovigilance (QPPV) in Saudi Arabia. For foreign MAHs, the agent relationship must also be documented through an Agency Registration Certificate issued by the Ministry of Commerce.
Obligations continue after approval: variations must be submitted for any change to the registered product, renewals filed before the authorization expires, and safety reporting maintained throughout the product's life on the Saudi market.
What changed in Version 6.4?
Version 6.4 refined submission and assessment stages and expanded the accelerated pathways available to innovative products, continuing the SFDA's shift toward reliance on reference authorities and faster patient access. For companies with products already approved by a recognized authority, the practical effect is that the verification route has become the default planning assumption rather than the exception.
How MRG supports drug approval in Saudi Arabia
MRG holds SFDA Consultation Office license CO-2023-FO-0022 and manages the full framework pathway for pharmaceutical companies: pathway classification and registration strategy, eCTD dossier preparation and SDR submission, query management during assessment, pricing file preparation, and post-approval variations and renewals — with regulatory teams in Saudi Arabia, the UAE, and Egypt.
If you are planning a Saudi submission, talk to our consultants about which pathway your product qualifies for, or explore our pharmaceutical regulatory services in Saudi Arabia — it is the first decision in the framework, and the one that determines everything after it.
Key Takeaway
The SFDA Regulatory Framework for Drug Approval (Version 6.4) defines four assessment routes — full, abridged, verification, and accelerated — and rewards products with recognized reference-authority approvals with substantially faster review. Success under the framework depends on correct pathway selection, a complete eCTD dossier submitted via the SDR platform, and disciplined query responses.
Frequently Asked Questions
What is the SFDA Regulatory Framework for Drug Approval?
It is the SFDA's published master document — currently Version 6.4 — defining every route to marketing authorization in Saudi Arabia: the assessment pathways, review timelines, submission requirements, and applicant responsibilities.
What are the SFDA drug registration pathways?
Four routes: full assessment for new chemical entities, abridged assessment leveraging reference-authority reviews, verification for products approved by recognized reference authorities, and accelerated programs such as the Breakthrough Medicine Program and conditional approval.
Which reference authorities does the SFDA recognize?
The US FDA, EMA, MHRA, Health Canada, TGA, PMDA, and Swissmedic. Approval from these authorities can qualify a product for the faster verification or abridged routes.
How long does SFDA drug approval take?
Published review clocks vary by pathway. End to end, companies should plan roughly nine to eighteen months for a generic on the verification or abridged route, including pricing review — longer for full-assessment products.
